K 040 284
APR 30 2004 t
510(K) Summary
Submitter: Cynosure, Inc.
10 Elizabeth Drive
Chelmsford, MA 01824

Contact: George Cho
Senior Vice President of Medical Technology

Date Summary Prepared: February 5, 2004

Device Trade Name: SmartLite D Laser

Common Name: Medical Laser System

Classification Name: Instrument, surgical, powered, laser
79-GEX
21 CFR 878.48

Equivalent Device: Fisma Elite Family of Lasers, ftequency doubled Nd:YAG
Fisma Dental 200, Dental 300, Dental 400

Device Description: SmartLite D is a frequency doubled Nd:YAG laser, having a Nd:YAG
crystal rod as the lasing medium. It is a laser with a wavelength of
532 nm.

Laser activation is by footswitch. Overall weight of the laser is 10 Kg,
and the size is 27x26x36 cm (HxWxD).
Electrical requirement is 230 VAC, 15A, 50-60 Hz, single phase.

Intended Use: The SmartLite D is indicated for ablation, incision, excision,
coagulation and vaporization of tissue in ophthalmology, dermatology,
ENT & dentistry.

Comparison: The SmartLite D laser has an equivalent indication for uses, the same
principle of operation, the same wavelength and essentially the same
pulse energy range as the predicate devices.

Nonclinical Performance Data: none

Clinical Performance Data: none

Conclusion: The SmartLite D laser is another safe and effective device for the
intended uses.

Additional [nformation: none

es
i & DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
~~ a
Food and Drug Administration
9200 Corporate Boulevard
APR 3 0 2004 Rodteville MD 20850
Mr. George Cho
Senior Vice President of Medical Technology
Cynosure, Inc. :
10 Elizabeth Drive
Chelmsford, Massachusetts 01824
Re: K040289
Trade/Device Name: SmartLite D Laser
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: February 5, 2004
Received: February 6, 2004
Dear Mr. Cho:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class [J (Special Controls) or class 11] (PMA), it
may be subject to such additional controls. Exi sting major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820), and if applicable, the electronic
product radiation control provisions (Sections 53 1-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. George Cho
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market. ,
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.gov/edrh/dsma/dsmamain.htm!

Sincerely yours,

Celia M. Witten, Ph.D., M.D. .

Director

Division of General, Restorative

‘ and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure :

Indications for Use
510(k) Number (ifknown): — JX _0 tt 0 1.84
Device Name: _ SmartLite D Laser
Indications For Use: The SmartLite D laser device is intended for ablation, incision, excision,
vaporization and coagulation of sofl tissue, in ophthalmology, ENT, and dermatology. In addition, the
laser is intended for application in dentistry including:
* Frenectomy
e Treatment of Oral Mucous Cysts
¢ Treatment of Benign Vascular Lesions
* Photocoagulation of Superficial Vessels /
¢ Vaporization of Superficial Blood Vessels or Lymphs Containing Vessels
« Treatment of Superficial Tongue Lesions
« Tissue Management and Hemostasis for Crown and Bridge Impressions
¢ Incision and Drainage for Abscess
e Gingivoplasty / Gingivectomy
¢ Hemostasis during Dental Procedures
¢ Operculectomy (Operculotomy)
e Excisional Biopsy
e Free Gingival Graft (Adjunct)
¢ Vestibuloplasty
« Soft Gutta Percha
¢ Treatment of Canker sores, Herpetic Lesions, and Aphthous Ulcers
e Laser-assisted Bleaching / Whitening of the Teeth
Prescription Use ___/ OR Over-The-Counter Use.
(Part 21 CFR 801 Subpart D) (Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE ~
Mul. 7 il
eae =

(Division Sign-Off)

Division of Genera!, Restorative,

and Neurological Lvices

1L040384
510(k) Number_—_—__—_——
Page f of 1

